The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pulmonary Arterial Hypertension (PAH) Medicine Market Research Report 2025
Synopsis
The global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Arterial Hypertension (PAH) Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Arterial Hypertension (PAH) Medicine.
Report Scope
The Pulmonary Arterial Hypertension (PAH) Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pulmonary Arterial Hypertension (PAH) Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Arterial Hypertension (PAH) Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Gilead Sciences
Eli Lilly
Actelion Pharmaceuticals
United Therapeutics Corporation
Segment by Type
Calcium Channel Blockers
Novel Targeted Drugs
Other
Segment by Application
Secondary Pulmonary Hypertension (SPH)
Primary Pulmonary Hypertension (PPH)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pulmonary Arterial Hypertension (PAH) Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Arterial Hypertension (PAH) Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Arterial Hypertension (PAH) Medicine.
Report Scope
The Pulmonary Arterial Hypertension (PAH) Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pulmonary Arterial Hypertension (PAH) Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Arterial Hypertension (PAH) Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Gilead Sciences
Eli Lilly
Actelion Pharmaceuticals
United Therapeutics Corporation
Segment by Type
Calcium Channel Blockers
Novel Targeted Drugs
Other
Segment by Application
Secondary Pulmonary Hypertension (SPH)
Primary Pulmonary Hypertension (PPH)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pulmonary Arterial Hypertension (PAH) Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pulmonary Arterial Hypertension (PAH) Medicine Market Overview
1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Medicine
1.2 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type
1.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Value Comparison by Type (2024-2030)
1.2.2 Calcium Channel Blockers
1.2.3 Novel Targeted Drugs
1.2.4 Other
1.3 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application
1.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Value by Application: (2024-2030)
1.3.2 Secondary Pulmonary Hypertension (SPH)
1.3.3 Primary Pulmonary Hypertension (PPH)
1.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Estimates and Forecasts
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue 2019-2030
1.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales 2019-2030
1.4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pulmonary Arterial Hypertension (PAH) Medicine Market Competition by Manufacturers
2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price by Manufacturers (2019-2024)
2.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Product Type & Application
2.7 Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Situation and Trends
2.7.1 Pulmonary Arterial Hypertension (PAH) Medicine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pulmonary Arterial Hypertension (PAH) Medicine Players Market Share by Revenue
2.7.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pulmonary Arterial Hypertension (PAH) Medicine Retrospective Market Scenario by Region
3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2019-2030
3.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2019-2024
3.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2025-2030
3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2019-2030
3.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2019-2024
3.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2025-2030
3.4 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
3.4.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2030)
3.4.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
3.5.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2030)
3.5.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
3.6.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2030)
3.6.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
3.7.1 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2030)
3.7.3 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country
3.8.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2019-2030)
4.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2019-2024)
4.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2025-2030)
4.1.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2019-2030)
4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2019-2030)
4.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2019-2024)
4.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2025-2030)
4.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2019-2030)
4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2019-2030)
5.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2019-2024)
5.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2025-2030)
5.1.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2019-2030)
5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2019-2030)
5.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2019-2024)
5.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2025-2030)
5.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2019-2030)
5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Gilead Sciences
6.2.1 Gilead Sciences Corporation Information
6.2.2 Gilead Sciences Description and Business Overview
6.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
6.2.5 Gilead Sciences Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Corporation Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Actelion Pharmaceuticals
6.4.1 Actelion Pharmaceuticals Corporation Information
6.4.2 Actelion Pharmaceuticals Description and Business Overview
6.4.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
6.4.5 Actelion Pharmaceuticals Recent Developments/Updates
6.5 United Therapeutics Corporation
6.5.1 United Therapeutics Corporation Corporation Information
6.5.2 United Therapeutics Corporation Description and Business Overview
6.5.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
6.5.5 United Therapeutics Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Chain Analysis
7.2 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pulmonary Arterial Hypertension (PAH) Medicine Production Mode & Process
7.4 Pulmonary Arterial Hypertension (PAH) Medicine Sales and Marketing
7.4.1 Pulmonary Arterial Hypertension (PAH) Medicine Sales Channels
7.4.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors
7.5 Pulmonary Arterial Hypertension (PAH) Medicine Customers
8 Pulmonary Arterial Hypertension (PAH) Medicine Market Dynamics
8.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends
8.2 Pulmonary Arterial Hypertension (PAH) Medicine Market Drivers
8.3 Pulmonary Arterial Hypertension (PAH) Medicine Market Challenges
8.4 Pulmonary Arterial Hypertension (PAH) Medicine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Pulmonary Arterial Hypertension (PAH) Medicine Average Price (USD/Units) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Pulmonary Arterial Hypertension (PAH) Medicine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Product Type & Application
Table 12. Global Key Manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pulmonary Arterial Hypertension (PAH) Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Medicine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2019-2024) & (K Units)
Table 18. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2019-2024)
Table 19. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2025-2030) & (K Units)
Table 20. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2025-2030)
Table 21. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2019-2024)
Table 23. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2025-2030)
Table 25. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2024) & (K Units)
Table 27. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2025-2030) & (K Units)
Table 28. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) by Type (2019-2024)
Table 51. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) by Type (2025-2030)
Table 52. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2019-2024)
Table 53. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2025-2030)
Table 54. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2019-2024)
Table 57. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2025-2030)
Table 58. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (USD/Units) by Type (2019-2024)
Table 59. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (USD/Units) by Type (2025-2030)
Table 60. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) by Application (2019-2024)
Table 61. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) by Application (2025-2030)
Table 62. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2019-2024)
Table 63. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2025-2030)
Table 64. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2019-2024)
Table 67. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2025-2030)
Table 68. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (USD/Units) by Application (2019-2024)
Table 69. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (USD/Units) by Application (2025-2030)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2019-2024)
Table 73. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Gilead Sciences Corporation Information
Table 76. Gilead Sciences Description and Business Overview
Table 77. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2019-2024)
Table 78. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product
Table 79. Gilead Sciences Recent Developments/Updates
Table 80. Eli Lilly Corporation Information
Table 81. Eli Lilly Description and Business Overview
Table 82. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2019-2024)
Table 83. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product
Table 84. Eli Lilly Recent Developments/Updates
Table 85. Actelion Pharmaceuticals Corporation Information
Table 86. Actelion Pharmaceuticals Description and Business Overview
Table 87. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2019-2024)
Table 88. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product
Table 89. Actelion Pharmaceuticals Recent Developments/Updates
Table 90. United Therapeutics Corporation Corporation Information
Table 91. United Therapeutics Corporation Description and Business Overview
Table 92. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2019-2024)
Table 93. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product
Table 94. United Therapeutics Corporation Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. Pulmonary Arterial Hypertension (PAH) Medicine Distributors List
Table 98. Pulmonary Arterial Hypertension (PAH) Medicine Customers List
Table 99. Pulmonary Arterial Hypertension (PAH) Medicine Market Trends
Table 100. Pulmonary Arterial Hypertension (PAH) Medicine Market Drivers
Table 101. Pulmonary Arterial Hypertension (PAH) Medicine Market Challenges
Table 102. Pulmonary Arterial Hypertension (PAH) Medicine Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Pulmonary Arterial Hypertension (PAH) Medicine
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Type in 2023 & 2030
Figure 4. Calcium Channel Blockers Product Picture
Figure 5. Novel Targeted Drugs Product Picture
Figure 6. Other Product Picture
Figure 7. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Application in 2023 & 2030
Figure 9. Secondary Pulmonary Hypertension (SPH)
Figure 10. Primary Pulmonary Hypertension (PPH)
Figure 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (2019-2030) & (US$ Million)
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (2019-2030) & (K Units)
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price (USD/Units) & (2019-2030)
Figure 15. Pulmonary Arterial Hypertension (PAH) Medicine Report Years Considered
Figure 16. Pulmonary Arterial Hypertension (PAH) Medicine Sales Share by Manufacturers in 2023
Figure 17. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Pulmonary Arterial Hypertension (PAH) Medicine Players: Market Share by Revenue in 2023
Figure 19. Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2019-2030)
Figure 22. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2019-2030)
Figure 23. U.S. Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2019-2030)
Figure 26. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2019-2030)
Figure 27. Germany Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2019-2030)
Figure 34. China Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2019-2030)
Figure 44. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Pulmonary Arterial Hypertension (PAH) Medicine by Type (2019-2030)
Figure 54. Global Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Medicine by Type (2019-2030)
Figure 55. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (USD/Units) by Type (2019-2030)
Figure 56. Global Sales Market Share of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2019-2030)
Figure 57. Global Revenue Market Share of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2019-2030)
Figure 58. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (USD/Units) by Application (2019-2030)
Figure 59. Pulmonary Arterial Hypertension (PAH) Medicine Value Chain
Figure 60. Pulmonary Arterial Hypertension (PAH) Medicine Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
